World Library  
Flag as Inappropriate
Email this Article

Quadazocine

Article Id: WHEBN0035586075
Reproduction Date:

Title: Quadazocine  
Author: World Heritage Encyclopedia
Language: English
Subject: List of opioids, Kobret, 6β-Naltrexol-d4, Hemorphin, Naloxonazine
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Quadazocine

Quadazocine
Systematic (IUPAC) name
1-cyclopentyl-5-[(1S,9R)-4-hydroxy-1,10,13-trimethyl-10-azatricyclo[7.3.1.02,7]trideca-2,4,6-trien-13-yl]-3-pentanone
Clinical data
Legal status
?
Identifiers
CAS number
ATC code None
PubChem
ChemSpider
UNII  YesY
Chemical data
Formula C25H37NO2 
Mol. mass 383.567 g/mol

Quadazocine (WIN-44,441) is an opioid antagonist of the benzomorphan family which is used in scientific research.[1] It acts as a silent antagonist at all three of the major opioid receptorsμ, κ, and δ,[1][2] but with a significant preference in affinity for the μ receptor and the κ2 subtype.[3][4][5] As such, it has been touted as a "κ2-selective" antagonist, though, of course, this is not entirely accurate on account of its similar affinity for the μ receptor.[3][5] As would be expected, quadazocine reverses the effects (e.g., analgesia) of opioid agonists like morphine and fentanyl in animals.[1][6]

References

  1. ^ a b c Ward SJ, Pierson AK, Michne WF (1983). "Multiple opioid receptor profile in vitro and activity in vivo of the potent opioid antagonist Win 44,441-3". Life Sciences. 33 Suppl 1: 303–6.  
  2. ^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). "Pharmacological profiles of opioid ligands at kappa opioid receptors". BMC Pharmacology 6: 3.  
  3. ^ a b Leon F. Tseng (1 September 1995). Pharmacology of Opioid Peptides. CRC Press. p. 238.  
  4. ^ Rao S. Rapaka; Wolfgang Sadée (13 June 2008). Drug Addiction: From Basic Research to Therapy. Springer. p. 421.  
  5. ^ a b Zhang WM, Wu S, Yu XC, Wang HX, Bian JS, Wong TM (February 1999). "Effects of U50488 and bremazocine on [Ca2+]i and cAMP in naive and tolerant rat ventricular myocytes: evidence of kappa opioid receptor multiplicity in the heart". Journal of Molecular and Cellular Cardiology 31 (2): 355–62.  
  6. ^ Negus SS, Zuzga DS, Mello NK (June 2002). "Sex differences in opioid antinociception in rhesus monkeys: antagonism of fentanyl and U50,488 by quadazocine". The Journal of Pain : Official Journal of the American Pain Society 3 (3): 218–26.  



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.